Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thaddeus H Grasela

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|March 26, 2009
Kerfuffle!Thaddeus H Grasela, Elizabeth Ludwig, Jill Fiedler-Kelly
Science (New York, N.Y.)|October 20, 2022
Regulatory insight from low-income countriesJackson K Mukonzo, David A Price, Thaddeus H Grasela
Clinical and Translational Science|April 9, 2021
COVID-19 vaccines and treatments: When speed is necessary and not enoughThaddeus H Grasela, David A Price, John A Wagner
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
The pharmacokinetic and pharmacodynamic profile of tigecyclineAlison K Meagher, Paul G Ambrose, Thaddeus H Grasela, et al.
Journal of Clinical Pharmacology|June 25, 2009
Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patientsSadahiro Abe, Koji Chiba, Brenda Cirincione, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agentAlison K Meagher, Paul G Ambrose, Thaddeus H Grasela, et al.
Journal of Pharmaceutical Sciences|September 25, 2025
Physiologically based pharmacokinetic modeling of hydroxyurea: Implications for dose adjustment in patients with renal insufficiencyHenry Enzama, Sandra Cvijic, Joshua Kiptoo, et al.
The Journal of Antimicrobial Chemotherapy|August 15, 2003
Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reductionPaul G Ambrose, Sujata M Bhavnani, Brenda B Cirincione, et al.
Clinical and Translational Science|April 27, 2026
Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug DevelopmentHenry Enzama, Francis Williams Ojara, Ian S Haworth, et al.
Surgical Infections|February 3, 2005
The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infectionPhilip S Barie, Ori D Rotstein, E Patchen Dellinger, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|March 26, 2009
Kerfuffle!Thaddeus H Grasela, Elizabeth Ludwig, Jill Fiedler-Kelly
Science (New York, N.Y.)|October 20, 2022
Regulatory insight from low-income countriesJackson K Mukonzo, David A Price, Thaddeus H Grasela
Clinical and Translational Science|April 9, 2021
COVID-19 vaccines and treatments: When speed is necessary and not enoughThaddeus H Grasela, David A Price, John A Wagner
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 5, 2005
The pharmacokinetic and pharmacodynamic profile of tigecyclineAlison K Meagher, Paul G Ambrose, Thaddeus H Grasela, et al.
Journal of Clinical Pharmacology|June 25, 2009
Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patientsSadahiro Abe, Koji Chiba, Brenda Cirincione, et al.
Diagnostic Microbiology and Infectious Disease|August 18, 2005
Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agentAlison K Meagher, Paul G Ambrose, Thaddeus H Grasela, et al.
Journal of Pharmaceutical Sciences|September 25, 2025
Physiologically based pharmacokinetic modeling of hydroxyurea: Implications for dose adjustment in patients with renal insufficiencyHenry Enzama, Sandra Cvijic, Joshua Kiptoo, et al.
The Journal of Antimicrobial Chemotherapy|August 15, 2003
Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reductionPaul G Ambrose, Sujata M Bhavnani, Brenda B Cirincione, et al.
Clinical and Translational Science|April 27, 2026
Advancing Pharmacoequity in Low- and Middle-Income Countries via Model Informed Drug DevelopmentHenry Enzama, Francis Williams Ojara, Ian S Haworth, et al.
Surgical Infections|February 3, 2005
The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infectionPhilip S Barie, Ori D Rotstein, E Patchen Dellinger, et al.
Pageof 2